Scholars@Duke publication: 657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway

657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway

Publication , Conference

Plebanek, M; DeVito, N; Liu, F; Theivanthiran, B; Beasley, G; Hanks, B

Published in: Journal for ImmunoTherapy of Cancer

November 2021

Journal for ImmunoTherapy of Cancer

2051-1426

November 2021

Suppl 2

A685 / A685

BMJ

APA

Chicago

ICMJE

MLA

NLM

Plebanek, M., DeVito, N., Liu, F., Theivanthiran, B., Beasley, G., & Hanks, B. (2021). 657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A685–A685). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.657

Plebanek, Michael, Nicholas DeVito, Fang Liu, Balamayooran Theivanthiran, Georgia Beasley, and Brent Hanks. “657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway.” In Journal for ImmunoTherapy of Cancer, 9:A685–A685. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.657.

Plebanek, Michael, et al. “657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A685–A685. Crossref, doi:10.1136/jitc-2021-sitc2021.657.